Loading…
Ataluren, a New Therapeutic for Alpha-1 Antitrypsin-Deficient Individuals with Nonsense Mutations
After sequencing of all coding exons (II-V) of the SERPINA1 gene, the patient was identified as homozygous for the Q0bolton mutation, with two PTCs at amino acid 373 and 374 on exon V. Molecular dynamics simulations of Q0bolton-AAT suggested sufficient interactions to stabilize native-like protein s...
Saved in:
Published in: | American journal of respiratory and critical care medicine 2018-10, Vol.198 (8), p.1099-1102 |
---|---|
Main Authors: | , , , , , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Summary: | After sequencing of all coding exons (II-V) of the SERPINA1 gene, the patient was identified as homozygous for the Q0bolton mutation, with two PTCs at amino acid 373 and 374 on exon V. Molecular dynamics simulations of Q0bolton-AAT suggested sufficient interactions to stabilize native-like protein structure, should it form during the early steps of protein folding. For Q0bolton-iPSC-hepatic cells, a significant 10-fold increase in AAT mRNA expression levels was observed compared with untreated cells (P < 0.05). [...]a significant 2-fold increase in the concentration of secreted Q0bolton-AAT protein was recorded with ataluren treatment (P < 0.001; Figure 2A). [...]for PTCs located more than 50 bp upstream of the most 3' exon-exon junction of the mRNA, nonsense-mediated decay is thought to eradicate the transcript (9). [...]this study demonstrates the potential use of ataluren to induce production and secretion of functional Q0bolton-AAT protein in vivo. |
---|---|
ISSN: | 1073-449X 1535-4970 |
DOI: | 10.1164/rccm.201802-0338LE |